Philip S. Low - May 19, 2022 Form 4 Insider Report for Cortexyme, Inc. (QNCX)

Role
Director
Signature
/s/ Chris Lowe, Attorney-in-Fact for Philip S. Low
Stock symbol
QNCX
Transactions as of
May 19, 2022
Transactions value $
$0
Form type
4
Date filed
5/23/2022, 08:17 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QNCX Common Stock Award +455K 455K May 19, 2022 Direct F1
transaction QNCX Common Stock Award +64K 64K May 19, 2022 By Philip S. Low Revocable Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Stock Option (right to buy) Award $0 +22.1K $0.00 22.1K May 19, 2022 Common Stock 22.1K $3.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.
F2 The shares subject to the option shall vest in equal annual installments over the three-year period following the grant date of May 19, 2022.